GenoFocus (Korea) Top Management
| 187420 Stock | 4,050 165.00 3.91% |
GenoFocus employs about 67 people. The company is managed by 4 executives with a total tenure of roughly 157 years, averaging almost 39.0 years of service per executive, having 16.75 employees per reported executive. Analysis of GenoFocus' management performance can provide insight into the company performance.
| JaeGu Pan Founder Founder CTO |
| TaekHo Yang Executive Head RD |
GenoFocus |
GenoFocus Management Team Effectiveness
The company has return on total asset (ROA) of (0.0291) % which means that it has lost $0.0291 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (24.4203) %, meaning that it generated substantial loss on money invested by shareholders. GenoFocus' management efficiency ratios could be used to measure how well GenoFocus manages its routine affairs as well as how well it operates its assets and liabilities.GenoFocus Workforce Comparison
GenoFocus is rated third in number of employees category among its peers. The total workforce of Materials industry is presently estimated at about 25,533. GenoFocus adds roughly 67.0 in number of employees claiming only tiny portion of all equities under Materials industry.
The company has Profit Margin (PM) of (0.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.25. GenoFocus Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. GenoFocus Price Series Summation is a cross summation of GenoFocus price series and its benchmark/peer.
GenoFocus Notable Stakeholders
A GenoFocus stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GenoFocus often face trade-offs trying to please all of them. GenoFocus' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GenoFocus' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JaeGu Pan | Founder CTO | Profile | |
| TaekHo Yang | Head RD | Profile | |
| EuiJoong Kim | Chief Officer | Profile | |
| JaeYoon Lee | Chief Officer | Profile |
About GenoFocus Management Performance
The success or failure of an entity such as GenoFocus often depends on how effective the management is. GenoFocus management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GenoFocus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GenoFocus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the presentation of GenoFocus' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GenoFocus' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of GenoFocus' management manipulating its earnings.
GenoFocus Workforce Analysis
Traditionally, organizations such as GenoFocus use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GenoFocus within its industry.GenoFocus Manpower Efficiency
Return on GenoFocus Manpower
| Revenue Per Employee | 386.2M | |
| Revenue Per Executive | 6.5B | |
| Net Loss Per Employee | 127.3M | |
| Net Loss Per Executive | 2.1B |
Complementary Tools for GenoFocus Stock analysis
When running GenoFocus' price analysis, check to measure GenoFocus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GenoFocus is operating at the current time. Most of GenoFocus' value examination focuses on studying past and present price action to predict the probability of GenoFocus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GenoFocus' price. Additionally, you may evaluate how the addition of GenoFocus to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |